<DOC>
	<DOCNO>NCT00262379</DOCNO>
	<brief_summary>The purpose demonstrate correction anemia hepatitis C virus treatment peginterferon plus ribavirin .</brief_summary>
	<brief_title>Use Non-use Epoetin Beta Patients Infected Chronic Hepatitis C</brief_title>
	<detailed_description>Show correction anemia epoetin beta ( NeoRecormon® ) able maintain optimal dose ribavirin ( Copegus® ) . The study compare two therapeutic strategy : use non-use epoetin beta ( NeoRecormon® ) patient infect chronic hepatitis C treat combination therapy Peginterferon alfa-2a ( Pegasys® ) plus ribavirin ( Copegus® ) . The main judgement criterion : - Sustained Viral Response ( Week 72 ) - Viral Response End Treatment ( Week 48 ) - Quality life - Cumulative dose ribavirin D0-W24 W24-W48 period - Clinical biological tolerance</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Male female patient 18 year old Patient French social security equivalent health assurance Patient inform consent Serologic evidence chronic hepatitis C detectable antiHCV antibody Patient infect HCV genotype 1 , 4 , 5 6 Compensated liver disease ( ChildPugh ≤ 6 ) Negative urine blood pregnancy test ( woman childbearing potential ) document within 24hour period prior enrollment study All fertile male females receive ribavirin must effective contraception treatment 6 following month Patient naive treatment installation treatment investigator follow criterion use Peginterferon alfa2a ( Pegasys ) ribavirin ( Copegus ) Women ongoing pregnancy breast feed Male partner pregnancy woman Minor Major protect French law biomedical study Coinfection HBV HIV History evidence decompensated liver disease ChildPugh score &gt; 6 Clinical radiological evidence ( abdominal ultrasound , CT scan MRI ) hepatocellular carcinoma IFN ribavirin previous time Patient receive erythropoetin within 2 month inclusion History epilepsy ( last 6 month ) Chronic cardiac insufficiency ( stage III IV classification New York Heart Association [ NYHA ] ) Not control portal hypertension Antecedents risk venous thrombosis Surgery within 3 month inclusion Serum creatinine level &gt; 15 mg/mL ( 130µmol/L ) Deficiency vitamin B9 and/or B12 ( suspect macrocytosis &gt; 105 µm3 ) Thrombocytosis ( platelet &gt; 500 000/mm3 ) Chronic inflammatory syndrome ( CRP &gt; 10 mg/L ) Deficiency correct iron : Ferritin blood level &lt; 10 µg/L Or Transferrin saturation coefficient &lt; 20 % History neoplasia ( except basocellular epithelioma cervical cancer ) Contraindications use epoetin beta excipient molecule study ( urea , polysorbate 20 , glycine , leucine , isoleucine , threonine , glutamic acid , phenylalanine , benzoic acid , benzyl alcohol ) Absence write informed consent Exclusion time another biomedical study Patient blood concentration hemoglobin low equal 12 g/dL male lower equal 11 g/dL female</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Chronic hepatitis C</keyword>
	<keyword>peginterferon</keyword>
	<keyword>ribavirin</keyword>
	<keyword>epoetin beta</keyword>
</DOC>